Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 14.8% in January

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 10,900 shares, a decrease of 14.8% from the December 31st total of 12,800 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned 0.20% of Aprea Therapeutics as of its most recent filing with the Securities & Exchange Commission. 34.19% of the stock is owned by institutional investors and hedge funds.

Aprea Therapeutics Trading Up 5.2 %

Shares of NASDAQ:APRE traded up $0.19 during trading on Thursday, hitting $3.90. 2,864 shares of the company’s stock were exchanged, compared to its average volume of 35,873. Aprea Therapeutics has a 1-year low of $2.15 and a 1-year high of $8.85. The firm has a 50-day moving average price of $3.46 and a two-hundred day moving average price of $3.46. The firm has a market cap of $21.20 million, a P/E ratio of -1.38 and a beta of 0.75.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.11. The company had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. As a group, research analysts predict that Aprea Therapeutics will post -2.55 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a report on Wednesday, January 15th.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.